IntOGen - PTEN gene cancer mutations in CBIOP_WXS_PRAD_SU2C

PTEN is detected as a mutational cancer driver in the Prostate Adenocarcinoma from SU2C-PCF Dream Team cohort

PTEN reports in Prostate Adenocarcinoma from SU2C-PCF Dream Team

Methods
Mutation distribution

Cohort details

Prostate Adenocarcinoma from SU2C-PCF Dream Team
Prostate Adenocarcinoma PRAD
444 Samples Driver genes 33 Mutations 64,566
Source SU2C-PCF Dream Team Reference PMID:31061129
Type Metastasis Treated Yes Age Adult Platform WXS

Gene details

PTEN
Gene ID ENSG00000171862 Transcript ID ENST00000371953 Protein ID ENSP00000361021
Mutated samples 15 Mutated samples (%) 3.38 Mutations 26
Known driver True

Method signals

Cohort	Methods	Samples	Samples (%)

ClustL HotMAPS smRegions Clustered Mutations
CBaSE dNdScv Recurrent Mutations
FML Functional Mutations
MutPanning Tri-nucleotide specific bias
combination Combination

Observed mutations in tumors

Show mutations as:

consequence type

driver classification

The mutations needle plot shows the distribution of the observed mutations along the protein sequence.

Highlight in X-axis:

Mutation (GRCh38)	Protein Position	Samples	Samples (%)	Consequence	Driver	Driver score

The excess of mutations per consequence type measures the percentage of driver mutations. More specifically, it quantifies the proportion of mutations among the ones that have been observed that are not explained by the neutral mutation model. The excess is obtained from the from the dNdScv estimates.